Top Page
Sareum Holdings
(LSE:SAR)
Sareum Holdings (SAR) vs. S&P 500 (SPY)
Sareum Holdings Business Overview & Revenue Model
Sareum Holdings Financial Statement Overview
| Breakdown | ||||
| Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 0.00 | 0.00 | 0.00 | 0.00 | 47.20K | Gross Profit |
| -1.00K | -1.00K | -2.00K | -1.09K | 47.20K | EBIT |
| -4.63M | -4.02M | -2.58M | -1.72M | -1.12M | EBITDA |
| -4.54M | -4.01M | -2.57M | -1.70M | -1.09M | Net Income Common Stockholders |
| -3.42M | -3.19M | -2.17M | -1.50M | -985.91K |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 1.46M | 994.00K | 4.26M | 2.69M | 1.80M | Total Assets |
| 2.77M | 2.02M | 4.79M | 3.08M | 2.00M | Total Debt |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Net Debt |
| -1.46M | -994.00K | -4.26M | -2.69M | -1.80M | Total Liabilities |
| 653.00K | 867.00K | 455.00K | 284.15K | 198.54K | Stockholders Equity |
| 2.11M | 1.15M | 4.33M | 2.80M | 1.80M |
| Cash Flow | Free Cash Flow | |||
| -3.92M | -3.27M | -2.13M | -1.57M | -816.35K | Operating Cash Flow |
| -3.89M | -3.27M | -2.13M | -1.57M | -813.09K | Investing Cash Flow |
| -23.00K | -41.00K | -2.00K | -37.86K | 1.29K | Financing Cash Flow |
| 4.38M | 0.00 | 3.71M | 2.49M | 1.70M |
Sareum Holdings Technical Analysis
Sareum Holdings Peers Comparison
Sareum Holdings Corporate Events
Sareum Holdings plc has announced the termination of the licensing agreement for its cancer drug candidate SRA737 by a U.S.-based biopharma company, effective in March 2025. Despite the setback, Sareum remains committed to advancing its pipeline of TYK2/JAK1 inhibitors, particularly focusing on SDC-1801, which is poised for Phase 2 development, thereby signaling a shift in strategic focus towards its in-house projects.
Sareum Holdings announced that all resolutions were passed during its Annual General Meeting, reflecting shareholder confidence in the company’s strategic direction. This outcome is significant for Sareum as it continues developing its promising kinase inhibitors, which have completed Phase 1 trials, potentially strengthening its position in the biotechnology market.
Sareum Holdings has made significant strides with its lead programme SDC-1801 by successfully completing a Phase 1 clinical trial, which demonstrated promising results for treating autoimmune diseases like psoriasis. The trial showed no serious adverse events, supporting its progression to Phase 2 trials with additional funding secured to meet regulatory requirements. Additionally, the company has strengthened its intellectual property with key patent milestones for SDC-1801 and continues to advance development on another kinase inhibitor, SDC-1802, for cancer immunotherapy. The licensing agreement for SRA737 with a US biopharma firm highlights Sareum’s strategic partnerships and potential for revenue generation.
Sareum Holdings PLC, a pharmaceutical company, has announced a change in its major holdings. Roger Meier, based in Horw, Switzerland, has acquired 4.04% of the voting rights in Sareum Holdings as of December 13, 2024. This acquisition, involving both direct voting rights and financial instruments, signifies a notable shift in shareholder composition which could influence strategic decisions within the company.
Sareum Holdings PLC announced the grant of share options to key executives and the transfer and exercise of shares and warrants, resulting in an adjustment of its share capital. The actions included the award of options over 4.4 million shares to top management, the transfer of shares between Dr. Tim Mitchell and his spouse, and the issuance of new shares due to exercised warrants and adviser fees. These moves aim to strengthen the company’s financial position and align management incentives, potentially impacting its market positioning and shareholder interests.